NAZ2329

NAZ2329

N658600-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ ( IC 50 =7.5 µM for hPTPRZ1) and PTPRG ( IC 50 =4.8 µM for hPTPRG) over other PTPs. NAZ232 Appearance:Solid IC50& Target:IC50: 7.5 µM (PTPRZ), 4.8 µM (PTPRG), 35.7 µM (PTPRA), 56.7 µM (PTPRM), 23.7 µM (PTPRS), 35.4 µM (PTPRB), 15.2 µM (PTPN6), 14.5 µM (PTPN1) In Vitro:NAZ2329 (0-25 µM; 48 hours) dose-dependently inhibits cell proliferation and migration in all cell lines (rat glioblastoma cells bearing C6 clone and human U251 glioblastoma cells). NAZ2329 (25 µM; 0-90 min) obviously promotes the phosphorylation lev In Vivo:NAZ2329 (22.5mg/kg; intraperitoneal injection; twice per week; 40 days) alone has a moderate inhibitory effect. However, the combination of Temozolomide and NAZ2329 exerts a significantly increased inhibition of tumor growth compared with the control gro Biological Activity:NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ ( IC 50 =7.5 µM for hPTPRZ1) and PTPRG ( IC 50 =4.8 µM for hPTPRG) over other PTPs. NAZ232

C21H18F3NO4S3

501.56 g/mol

CCOC1=C(CSC2=C(C(NS(=O)(C3=CC=CC=C3)=O)=O)SC=C2)C=C(C(F)(F)F)C=C1

DMSO : 100 mg/mL (199.38 mM; Need ultrasonic)